Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8WU66
UPID:
TSEAR_HUMAN
Alternative names:
-
Alternative UPACC:
Q8WU66
Background:
The Thrombospondin-type laminin G domain and EAR repeat-containing protein plays a pivotal role in the morphogenesis of teeth and hair follicles, primarily through the modulation of the Notch signaling pathway. Additionally, it may contribute to the development or functionality of the auditory system.
Therapeutic significance:
Linked to diseases such as Deafness, autosomal recessive, 98, Ectodermal dysplasia 14, and Selective tooth agenesis, 10, this protein's understanding could pave the way for innovative treatments targeting these conditions.